Log In
Print
BCIQ
Print
Print this Print this
 

KD019, XL647

  Manage Alerts
Collapse Summary General Information
Company Kadmon Corp. LLC
DescriptionReversible tyrosine kinase inhibitor targeting epidermal growth factor receptor (EGFR), VEGFR-2, VEGFR-3, and HER2/neu/ErbB2 receptor
Molecular Target Epidermal growth factor receptor 2 (HER2) (EGFR2) (ErbB2) (neu) ; Vascular endothelial growth factor (VEGF) receptor 2 (VEGFR-2) (KDR/Flk-1)
Mechanism of Action 
Therapeutic Modality 

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Get a free BioCentury trial today